Revenue Beat and Packed Calendar Lift ANAB After Earnings
AnaptysBio climbed in premarket after a $27.5M collaboration-revenue beat. Jemperli sales grew 26–34%; ignore the $5.11 EPS tax gain.
/ 4 items
#ANAB↓
GSK and AnaptysBio Enter Legal Battle Over Cancer Drug Jemperli
GSK subsidiary Tesaro and AnaptysBio file dueling lawsuits in Delaware court over alleged breaches of their 2014 Jemperli licensing agreement, with trial set for July 2026.
AnaptysBio ends UC trial, advances RA program, plans 2026 split
Rosnilimab UC trial discontinued after failing efficacy endpoint. AnaptysBio advances RA program & ANB033 (CeD). Plans firm for 2026 corporate split.
AnaptysBio Plans to Split into Two Independent Companies
AnaptysBio announced plans to separate its business into 'Royalty Management Co' and 'Biopharma Co' by late 2026, aiming to unlock the potential value of its immunology pipeline and royalty assets.